Title: Comparison of Pegfilgrastim with Filgrastim in Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients
Authors: Dr Anima Rout, Dr Prashant Parida, Dr Priti Das, Dr Jyotiranjan Nayak, Dr Srikanta Mohanty
DOI: https://dx.doi.org/10.18535/jmscr/v7i1.174
Abstract
Background & Objective: Granulocyte Colony Stimulating Factor (G-CSF) is a glycoprotein, helps in producing cells from bone marrow. Pharmaceutical analogs of naturally occurring G-CSF are used in chemotherapy induced neutropenia to prevent infections and sepsis. This study compares the efficacy and safety of single fixed dose of pegfilgrastim (pegylated form of filgratim) versus daily administration of filgrastim in breast cancer patients
Patients and Method: Patients (n=80) with confirmed diagnosis of breast cancer receiving chemotherapy regimen (cyclophosphamide+doxorubicin+paclitaxel) were randomised in 2 groups. One group received pegfilgrastim 6 mg subcutaneously & the other group received filgrastim 300 mcg consecutively for 3 days on day 2 of chemotherapy cycle.The primary end point was the occurrence of febrile neutropenia (neutrophil count <4000 and fever on same day or the day after).The secondary end points were duration of hospitalizations, intravenous (IV) antibiotics required for neutropenia, and episodes of anemia.
Any adverse drug reaction (ADR) related to study drug were observed.
Results: Forty patients were analysed in each group (176 cycles in group 1 & 197 cycles in group 2). Neutropenia developed in 5.6% & 11.6% (p<0.0423), mean duration of hospital stay were 3-4 days & 5-6 days, i.v antibiotic usage was4% & 7%. 25% of patients in group 1 and 29% in group 2 suffered from anemia and required blood transfusion respectively. Bone pain was the most common ADR found due to filgrastim.
Conclusion: Single dose of pegfilgrastim were significantly better than 3 doses of filgrastim for reducing Neutropenia rate in breast cancer patients receiving chemotherapy.
Keywords: G-CSF (Pegfilgrastim, filgrastim), Breast cancer, Neutropenia.
References
Cameron D, Appro M. Managing myelotoxicities of breast cancer chemotherapies: what is the role for G-CSF? EJC Supplements; 2008: S6: 1 7–2 3
[1] Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC cancer. 2011;11(1):1.
[1] von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer. 2009 Mar;45(4):608-17. doi: 10.1016/j.ejca.2008.11.021.
[1] Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916–1924.
[1] Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer
[1] Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
[1] Kuderer N, Dale D, Crawford J, Cosler L, Lyman G: Mortality, Morbidity, and Cost Associated with Febrile Neutropenia in Adult Cancer Patients. CANCER 2006, 106:2258-2266.
[1] Caselli D, Aricò M, Cesaro S. Biosimilars in the management of neutropenia: focus on filgrastim. Biologics: Targets and Therapy. 2016 Feb;17.
[1] Raposo CG, Marin AP, Baron MG. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Transl Oncol. 2006;8:729–734.
[1] Biesma B, Vellenga E, Willemse PH, de Vries EG. Effects of hematopoietic growth factors on chemotherapy-induced myelosuppression. Critical reviews in oncology/hematology. 1992;13(2):107–134.
[1] Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G: Filgrastim (rmetHuG-CSF): the first 10 years. Blood 1996, 88:1907-1929.
[1] Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Critical Reviews in Oncology/ Hematology. 2011 Apr;78(1):17–23.
[1] Del Giglio A, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle I in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332–8.
[1] Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 2002;9:207–14.
[1] Bhattacharyya GS, Malhotra H, Ranade AA, Raghunadharao D. Everyone is concerned about costs! Indian J Cancer. 2009 Jul-Sep;46(3):179-81. PubMed PMID: 19574666.
[1] Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manage Care Pharm 2003;9(2 Suppl.):15–21.
[1] National Cancer Registry Program. Three-year Report of Population Based Cancer Registries: 2012-2014. Report of 27 PBCRs in India. Indian Council of Medical Research 2016: p9. [Cited 2016 Aug 27] Available from: http://ncrpindia.org/ALL_NCRP_REPORTS/PBCR_REPORT_2012_2014/ALL_CONTENT/PDF_Printed_Version/Chapter2_Printed.pdf]
[1] Khan M A, Bahadur A K, Agarwal P N, Sehgal A, Das B C. Psychosocial disorders in women undergoing postoperative radiation and chemotherapy for breast cancer in India. Indian J Cancer [serial online] 2010 [cited 2016 Aug 27];47:296-303. Available from: http://www.indianjcancer.com/text.asp?2010/47/3/296/64729
[1] Agarwal G, Ramakant P. Breast Cancer Care in India: The Current Scenario and the Challenges for the Future. Breast Care (Basel). 2008 Mar;3(1):21–7.
[1] Roy V, Saxena D, Agarwal M, Bahadur A, Mishra B. Use of antimicrobial agents and granulocyte colony stimulating factors for febrile neutropenia in cancer patients in a tertiary care hospital in India. Indian Journal of Cancer. 2010;47(4):430.
Xxi Balducci L1, Yates J. Oncology (Williston Park). 2000 Nov;14(11A):221-7. General guidelines for the management of older patients with cancer.
Xxii Mallik S, Palaian S, Ojha P, Mishra P. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal. Pak J Pharm Sci 2007;20:214-8
.xxiii. Poddar S, Sultana R. Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh. Dhaka Univ J Pharm Sci 2009;8:11-6
xxiv. NCCN guidelines for patients. Breast cancer- Early-Stage(Stage I AND II), version1.2016
xxv.Ogawa M.Differentiation and proliferation of haematopoietic stem cells. Blood. 1993; 81: 2844-2853
xxvi. Flemming W.H. and Weissman I.L.. Haematopoietic stem cells. In:Abeloff M.D., Armitage J.O., Lichter A.S. and Neiderhuber J.E., Eds Clinical Oncology. Churchill Livingstone. 1995; 127-133
xxvii. Holmes FA, O’Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731.
xxviii.M. D. Green1*, H. Koelbl2, J. Baselga3, A. Galid4, V. Guillem5, P. Gascon6, S. Siena7, R. I. Lalisang8, H. Samonigg9, M. R. Clemens10, V. Zani11, B. C. Liang11, J. Renwick11 & M. J. Piccart12A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
xxix.Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll, Sergei A. Tjulandin,Luis Javier Barajas-Figueroa, Brian L. Wiens, Theresa A. Neumann, and Lee S. Schwartzberg. First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
xxx. Paola Papaldo, Massimo Lopez, Paolo Marolla, Enrico Cortesi, Mauro Antimi, Edmondo Terzoli,Patrizia Vici, Carlo Barone, Gianluigi Ferretti, Serena Di Cosimo, Paolo Carlini, Cecilia Nistico`,Francesca Conti, Luigi Di Lauro, Claudio Botti, Franco Di Filippo, Alessandra Fabi, Diana Giannarelli,and Federico Calabresi .Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. Journal of clinical oncology. Volume 23, October 2005
xxxi. Ozer H, Armitage JO, Bennett CL, et al:2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines— American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-3585, 2000
xxxii. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
xxxiii. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003
xxxiv. Lobil S, von Minckwitz G, Harbeck N, et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4500 patients from four German randomised breast cancer trials.Breast Cancer Rees 2008;10;R77